Keros Therapeutics (KROS) - Bathi resik saben saham (EPS TTM)

Keros Therapeutics (KROS) is developing an advanced treatment system for blood pathologies, establishing new industry standards. Comparing the rolling annual earnings per share trend on GURU.Markets, we see that the -2.85 level indicates the status of the parameter. Keros Therapeutics reduces capital risks through a diverse pipeline of biologics for musculoskeletal and hematological diseases. However, the absence of commercial sales and rising trial costs necessitate continuous external financing.
Rincian metrik komprehensif lan analitis Keros Pharma (KROS)

Keros Therapeutics (KROS) minimizes operational risks by outsourcing drug development and clinical trials to third-party contractors. This rolling annual earnings per share chart reflects the ultimate effectiveness of this strategy, converting the aggregate net result into per-share income to assess the real return on capital and the fundamental value of asset ownership.